Literature DB >> 18716731

Complete resolution of a mitral valve vegetation with anticoagulation in seronegative antiphospholipid syndrome.

Yuheng Ruan1, Jonathan S Bridges, Kapil Kumar, Jonelle A Raphael, Subroto Acharjee, Francine K Welty.   

Abstract

Antiphospholipid syndrome (APS) is a disorder characterized by recurrent venous or arterial thrombosis and/or fetal loss; involvement of cardiac valves is also seen. A seronegative variant has been described previously. We report a case of a woman with recurrent pregnancy loss, prior strokes, and a negative workup for known antiphospholipid antibodies. During her current pregnancy, she presented with acute stroke and mitral valve vegetation. Her workup for antiphospholipid syndrome and other thrombophilias remained negative even after the stroke. Her mitral valve vegetation resolved completely with aspirin, heparin, and warfarin. We believe this to be the first report of complete resolution of valvular vegetation with antiplatelet and anticoagulant therapy alone in a patient with seronegative antiphospholipid syndrome. Moreover, this appears to be the first report of stroke associated with this condition.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18716731     DOI: 10.1007/s10067-008-0991-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  10 in total

Review 1.  International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop.

Authors:  W A Wilson; A E Gharavi; T Koike; M D Lockshin; D W Branch; J C Piette; R Brey; R Derksen; E N Harris; G R Hughes; D A Triplett; M A Khamashta
Journal:  Arthritis Rheum       Date:  1999-07

2.  Seronegative antiphospholipid syndrome.

Authors:  G R V Hughes; M A Khamashta
Journal:  Ann Rheum Dis       Date:  2003-12       Impact factor: 19.103

3.  Severe limb necrosis: primary thrombotic microangiopathy or "seronegative" catastrophic antiphospholipid syndrome? A diagnostic dilemma.

Authors:  I Lazurova; Z Macejova; Z Tomkova; F Remenar; A Boor; J Lazur; R Roland; J Rovensky; R A Asherson
Journal:  Clin Rheumatol       Date:  2007-01-26       Impact factor: 2.980

4.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

5.  Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome.

Authors:  Maurizio Turiel; Piercarlo Sarzi-Puttini; Rossana Peretti; Sara Bonizzato; Sabrina Muzzupappa; Fabiola Atzeni; Edoardo Rossi; Andrea Doria
Journal:  Am J Cardiol       Date:  2005-08-15       Impact factor: 2.778

6.  Seronegative antiphospholipid syndrome associated with plasminogen activator inhibitor.

Authors:  J Joseph; E Scopelitis
Journal:  Lupus       Date:  1994-06       Impact factor: 2.911

7.  Validation of the Sapporo criteria for antiphospholipid syndrome.

Authors:  M D Lockshin; L R Sammaritano; S Schwartzman
Journal:  Arthritis Rheum       Date:  2000-02

8.  Primary antiphospholipid syndrome: a 5-year transesophageal echocardiographic followup study.

Authors:  Nilda Espinola Zavaleta; Rosa María Montes; María Elena Soto; Nidia Avila Vanzzini; Mary-Carmen Amigo
Journal:  J Rheumatol       Date:  2004-12       Impact factor: 4.666

9.  Increased morbidity and mortality in patients with antiphospholipid syndrome undergoing valve replacement surgery.

Authors:  Yackov Berkun; Amir Elami; Karen Meir; Dror Mevorach; Yaakov Naparstek
Journal:  J Thorac Cardiovasc Surg       Date:  2004-02       Impact factor: 5.209

10.  Anticardiolipin antibodies: clinical consequences of "low titers".

Authors:  R M Silver; T F Porter; I van Leeuween; G Jeng; J R Scott; D W Branch
Journal:  Obstet Gynecol       Date:  1996-04       Impact factor: 7.661

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.